New hope for amyloidosis patients in major drug trial
NCT ID NCT07388602
Summary
This study is testing whether adding a new drug called SCTC21C to a standard treatment works better for people newly diagnosed with light-chain amyloidosis. Researchers will compare the drug combination against the standard treatment alone in 90 participants. The goal is to see if the new combination helps more people achieve a deep response and prevents organ damage from this serious disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.